関西医科大学附属病院 新薬開発科
  • Top
  • Mission
  • Faculty & Staff
  • Ongoing phase 1 trials
  • News
  • Contact Us

News

PickupTopics

  • 202511/27

    GSK5460025 (GlaxoSmithKline) Global First Subject First Dose

    On November 5, 2025, the Department of New Experimental Therapeutic...

    View More

  • 202511/05

    NEXT Oncology Expands to Japan in Joint Venture Partnership With Kansai Medical Univ...

    View More

  • 202509/01

    Expanding FIH Phase 1 Inpatient Wards for Reinforcing Early Phase Oncology Clinical ...

    Expanding FIH Phase 1 inpatient wards for reinforcing early phase o...

    View More

  • 202507/08

    AbbVie ABBV-324 -First Administration of Investigational Cancer Drug in Asia (Global...

    On July 8, 2025, the Department of New Experimental Therapeutics an...

    View More

  • 202506/17

    Boehringer Ingelheim BI770371’s NCT06806852 trial – the “First patient i...

    On June 17, 2025, the Department of New Experimental Therapeutics a...

    View More

  • 202505/30

    Selected to be AbbVie’s Phase 1 Partnerships for Excellence in Research (P1PER) Glob...

    Department of New Experimental Therapeutics, Early-Phase 1 Drug Dev...

    View More

<1 2 3>
関西医科大学附属病院 新薬開発科

Department of New Experimental Therapeutics
Early-Phase 1 Drug Development Service
Kansai Medical University Hospital

Address: 3-1 Shinmachi 2 Chome, Hirakata City,
Osaka, Japan 573-1191,Japan
Tel : 072-804-0101

  • Top
  • Mission
  • Faculty & Staff
  • Ongoing phase 1 trials
  • News
  • Contact Us

ⓒ2025 Kansai medical university All rights reserved.